CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis

[1]  W. Roush,et al.  Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. , 2019, Cancer cell.

[2]  Ning Zhang,et al.  circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Qiang Zhang,et al.  Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression , 2019, Molecular Cancer.

[4]  Renbing Jia,et al.  The novel roles of circRNAs in human cancer , 2019, Molecular Cancer.

[5]  Man-Li Zhang,et al.  Dysregulation of p53-RBM25-mediated circAMOTL1L biogenesis contributes to prostate cancer progression through the circAMOTL1L-miR-193a-5p-Pcdha pathway , 2018, Oncogene.

[6]  E. Antonarakis.  Cyclin‐Dependent Kinase 12, Immunity, and Prostate Cancer , 2018, The New England journal of medicine.

[7]  CDK12 Changes Telling in Prostate Cancer. , 2018, Cancer discovery.

[8]  Z. Zeng,et al.  Circular RNAs (circRNAs) in cancer. , 2018, Cancer letters.

[9]  A. Chinnaiyan,et al.  Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer , 2018, Cell.

[10]  Qizhan Liu,et al.  Exosomal circRNA_100284 from arsenite-transformed cells, via microRNA-217 regulation of EZH2, is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation , 2018, Cell Death & Disease.

[11]  Man-Li Zhang,et al.  Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel , 2017, Journal of experimental & clinical cancer research : CR.

[12]  Toru Suzuki,et al.  A Novel Regulatory Mechanism of Smooth Muscle &agr;-Actin Expression by NRG-1/circACTA2/miR-548f-5p Axis , 2017, Circulation research.

[13]  A. Kehlen,et al.  Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis , 2016, Scientific Reports.

[14]  N. Hannett,et al.  Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. , 2016, Nature chemical biology.

[15]  Yan Li,et al.  Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs , 2016, Nature Communications.

[16]  M. Geyer,et al.  Structural and Functional Analysis of the Cdk13/Cyclin K Complex. , 2016, Cell reports.

[17]  Diarmaid Hughes,et al.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms , 2015, Nature Reviews Genetics.

[18]  Zujiang Yu,et al.  Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth , 2015, Scientific Reports.

[19]  L. Galluzzi,et al.  Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition , 2015, Oncogene.

[20]  G. Shan,et al.  Exon-intron circular RNAs regulate transcription in the nucleus , 2015, Nature Structural &Molecular Biology.

[21]  A. Shilatifard,et al.  Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing , 2015, Molecular and Cellular Biology.

[22]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[23]  Cheng Huang,et al.  Promising roles of mammalian E2Fs in hepatocellular carcinoma. , 2014, Cellular signalling.

[24]  L. Galluzzi,et al.  Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition , 2014, Oncogene.

[25]  D. Ichikawa,et al.  E2F5 as an independent prognostic factor in esophageal squamous cell carcinoma. , 2013, Anticancer research.

[26]  J. Joung,et al.  Radium Ra 223 dichloride in castration-resistant prostate cancer. , 2013, Drugs of today.

[27]  H. Klocker,et al.  Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. , 2012, The American journal of pathology.

[28]  J. Nevins,et al.  A role for Mediator complex subunit MED13L in Rb/E2F-induced growth arrest , 2012, Oncogene.

[29]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[30]  Y. Ming,et al.  Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. , 2012, Oncology letters.

[31]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[32]  M. Kami,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[33]  Shih-Yin Tsai,et al.  Emerging roles of E2Fs in cancer: an exit from cell cycle control , 2009, Nature Reviews Cancer.

[34]  M. Daidone,et al.  miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. , 2009, Cancer research.

[35]  M. Shirane,et al.  Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome , 2009, British Journal of Cancer.

[36]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[37]  A. Genevière,et al.  CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. , 2007, Biochemical and biophysical research communications.

[38]  H. Phatnani,et al.  Phosphorylation and functions of the RNA polymerase II CTD. , 2006, Genes & development.

[39]  D. Tindall,et al.  Molecular regulation of androgen action in prostate cancer , 2006, Journal of cellular biochemistry.

[40]  R. Bast,et al.  Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer , 2006, Clinical Cancer Research.

[41]  R. Fisher.  Secrets of a double agent: CDK7 in cell-cycle control and transcription , 2005, Journal of Cell Science.

[42]  P. Loyer,et al.  Role of CDK/cyclin complexes in transcription and RNA splicing. , 2005, Cellular signalling.

[43]  H. Klocker,et al.  Targeting the androgen receptor in hormone-refractory prostate cancer--new concepts. , 2005, Future oncology.

[44]  K. Helin,et al.  The E2F family: specific functions and overlapping interests , 2004, The EMBO journal.

[45]  R. Agarwal,et al.  Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. , 2003, Carcinogenesis.

[46]  C. Sardet,et al.  Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors , 2000, Genes, chromosomes & cancer.

[47]  M. Suri,et al.  CDK13-related disorder. , 2019, Advances in genetics.

[48]  Jørgen Kjems,et al.  Circular RNAs: Identification, biogenesis and function. , 2016, Biochimica et biophysica acta.

[49]  C. Nabhan.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer , 2015 .

[50]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[51]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[52]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[53]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[54]  Hung-Hsi Chen,et al.  Identification and Characterization of the CDK12/Cyclin L1 Complex Involved in Alternative Splicing Regulation† , 2022 .